It is said that new CEO Emma Walmsley is on the brink of reshuffling the brand portfolio, with the sports nutrition business, bought only in 2010 for £162/$205 million, up for grabs.
Walmsley has been on board with GSK since April 1st.
If sold, this would represent a departure from sports nutrition for GSK, which also sold the Lucozade label in 2013 for £1.35 billion to Japan’s Suntory.
Further indications detailing the future of the portfolio will likely come to fruition in next month’s half-year financials. It is believed that Walmsley is keen to priorities GSK’s prescription drugs trade over off shoot brands.